Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics presented new analyses from its NAVIGATE trial at EASL 2026, showing belapectin significantly reduces new varices development in high-risk MASH cirrhosis patients. The oral presentation demonstrated a mechanistic link between fibrogenesis modulation and reduced varices, while a designated TOP Poster showed significant reductions in clinically significant portal hypertension risk.
Key figures
- Drug Name
- belapectin
- Phase Of Trial
- Phase 3
- Liver stiffness p value
- 0.03
- Varices reduction p value
- 0.04
- Baveno improvement p value
- 0.0073
- Liver stiffness worsening placebo
- 23.9%
- Liver stiffness worsening belapectin
- 11.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.